Results 241 to 250 of about 2,184,937 (297)
Some of the next articles are maybe not open access.

Midazolam kinetics

Clinical Pharmacology and Therapeutics, 1981
The effect-kinetics of the new benzodiazepine midazolam was evaluated in six subjects after single oral (7.5 and 15 mg) and intravenous (0.075 mg/kg) doses and infusion programs. The drug is bound to plasma proteins by 94%, and less than 0.5% is excreted unchanged in urine.
H, Allonen, G, Ziegler, U, Klotz
openaire   +2 more sources

Piperacillin kinetics

Clinical Pharmacology & Therapeutics, 1979
Piperacillin was administered to normal, healthy volunteers by an intravenous infusion over 30 min at dosage regimens of 12 gm daily (4 gm every 8 hr) and 24 gm daily (6 gm every 6 hr) for 5 consecutive days. Mean peak serum level after 12 gm daily was 244 ± 24 (SE) βg/ml and after 24 gm daily, 353 ± 7 βg/ml.
V K, Batra   +3 more
openaire   +2 more sources

Kinetic Proofreading

Annual Review of Biochemistry, 2022
Biochemistry and molecular biology rely on the recognition of structural complementarity between molecules. Molecular interactions must be both quickly reversible, i.e., tenuous, and specific. How the cell reconciles these conflicting demands is the subject of this article.
openaire   +2 more sources

Flavoprotein Kinetics

2003
Flavoproteins are ubiquitous proteins involved in diverse biological processes ranging from redox catalysis and light emission to DNA repair (1). Based on their function, flavoproteins can be divided into several subclasses including electron transferases, photolyases, synthases, dehydrogenases, disulfide reductases, oxidases, and monooxygenases.
van Berkel, W.J.H.   +3 more
openaire   +2 more sources

Acetylcholinesterase kinetics

Biophysics of Structure and Mechanism, 1980
Three mechanisms have been suggested to describe the inhibition of acetylcholinesterase (EC. 3.1.1.7) by an excess of acetylcholine. (i) Substrate inhibition occurs through the reaction of acetylcholine with acetylated enzyme. The deacetylation of this ternary complex is supposed to be completely inhibited.
P, Hofer, U P, Fringeli
openaire   +2 more sources

Captopril kinetics

Clinical Pharmacology and Therapeutics, 1982
Captopril, an angiotensin-converting enzyme inhibitor with antihypertensive properties, was given by mouth and intravenously in 10-mg doses to five healthy subjects. After intravenous dosing, semilogarithmic plots of captopril blood levels : time showed a triexponential decay. Data were analyzed using an open three-compartment model. The average volume
K L, Duchin   +4 more
openaire   +2 more sources

Protriptyline kinetics

Clinical Pharmacology & Therapeutics, 1978
The kinetics of protriptyline were examined in 8 subjects after a single oral dose of 30 mg protriptyline hydrochloride. Peak protriptyline levels ranged from 10.4 to 22.3 ng/ml and were reached 6 to 12 hr after the oral dose. The mean protriptyline half‐life (t½) was 74.3 hr and ranged from 53.6 to 91.7 hr in individual subjects, confirming the long ...
V E, Ziegler   +6 more
openaire   +2 more sources

Ceforanide kinetics

Clinical Pharmacology and Therapeutics, 1981
Pharmacologic studies of the semisynthetic cephalosporin ceforanide were conducted in 29 cancer patients. Intravenous doses of 500 mg over 30 min every 6 hr to 10 patients induced mean peak serum concentrations between 44.7 and 51.5 micrograms/ml, while in 10 patients receiving 1 gm over 30 min every 12 hr mean peak serum concentrations varied from 73 ...
E H, Estey   +5 more
openaire   +2 more sources

Busulfan kinetics

Clinical Pharmacology and Therapeutics, 1983
Busulfan kinetics were studied in patients with chronic myelocytic leukemia after oral doses of 2, 4, and 6 mg. The plasma concentration-time data could be fitted to a zero-order absorption one-compartment open model. The elimination rate constant averaged 0.27 +/- 0.05 hr-1 (SD). The plasma AUC was linearly related to the dose.
H, Ehrsson   +3 more
openaire   +2 more sources

Tolrestat kinetics

Clinical Pharmacology and Therapeutics, 1984
The kinetics of tolrestat, a potent inhibitor of aldose reductase, were examined. Serum concentrations of tolrestat and of total 14C were measured after dosing normal subjects and subjects with diabetes with 14C-labeled tolrestat. In normal subjects, tolrestat was rapidly absorbed and disappearance from serum was biphasic.
D R, Hicks   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy